Objective: To explore the clinical efficacy and safety of autologous platelet-rich plasma (PRP) eye drops in treating moderate to severe dry eye syndrome (SS). Method: A prospective randomized controlled study was conducted, including 60 patients with SS and moderate to severe dry eye syndrome admitted to the First People’s Hospital of Jingzhou from May 2024 to May 2025. The patients were randomly divided into the PRP group (n = 30) and the control group (n = 30). The PRP group received autologous PRP eye drops, while the control group used 0.3% sodium hyaluronate eye drops, both administered three times daily for one month. The primary outcome measures included changes in the Schirmer test, tear film break-up time (BUT), and corneal conjunctival fluorescein staining (CFS) scores before and after treatment, along with recording any adverse reactions. Results: After treatment, the PRP group showed significantly better Schirmer test values (6.8 ± 1.5 mm vs 4.5 ± 1.2 mm) and BUT (8.2 ± 1.2s vs 5.0 ± 0.9 s) compared to the control group, with a significant decrease in CFS scores (3.1 ± 0.8 vs 5.2 ± 1.3) (all P < 0.05). There was no statistically significant difference in adverse reaction rates between the two groups (13.3% vs 10.0%, P > 0.05). Conclusion: Autologous PRP eye drops can effectively improve dry eye symptoms in SS patients, promote ocular surface repair, and have good safety and clinical application value.
References
[1]
Mariette, X. and Criswell, L.A. (2018) Primary Sjögren’s Syndrome. New England Journal of Medicine, 378, 931-939. https://doi.org/10.1056/nejmcp1702514
[2]
Zhan, Q., Zhang, J., Lin, Y., Chen, W., Fan, X. and Zhang, D. (2023) Pathogenesis and Treatment of Sjogren’s Syndrome: Review and Update. Frontiers in Immunology, 14, Article 1127417. https://doi.org/10.3389/fimmu.2023.1127417
[3]
Pucker, A.D., Ng, S.M. and Nichols, J.J. (2016) Over the Counter (OTC) Artificial Tear Drops for Dry Eye Syndrome. Cochrane Database of Systematic Reviews, 2, CD009729. https://doi.org/10.1002/14651858.cd009729.pub2
[4]
Harke, H.,Tanger, D., Fürst-Denzer, S., et al. (1977) Effect of a Preoperative Separation of Platelets on the Postoperative Blood Loss Subsequent to Extracorporeal Circulation in Open Heart Surgery. Der Anaesthesist, 26, 64-71.
[5]
Wróbel-Dudzińska, D., Przekora, A., Kazimierczak, P., Ćwiklińska-Haszcz, A., Kosior-Jarecka, E. and Żarnowski, T. (2023) The Comparison between the Composition of 100% Autologous Serum and 100% Platelet-Rich Plasma Eye Drops and Their Impact on the Treatment Effectiveness of Dry Eye Disease in Primary Sjogren Syndrome. Journal of Clinical Medicine, 12, Article 3126. https://doi.org/10.3390/jcm12093126
[6]
Vitali, C., Bombardieri, S., Jonsson, R., Moutsopoulos, H.M., Alexander, E.L., Carsons, S.E., et al. (2002) Classification Criteria for Sjögren’s Syndrome: A Revised Version of the European Criteria Proposed by the American-European Consensus Group. Annals of the Rheumatic Diseases, 61, 554-558. https://doi.org/10.1136/ard.61.6.554
[7]
Jongkhajornpong, P., Lekhanont, K., Rattanasiri, S., Pisitkun, P. and Thakkinstian, A. (2024) Comparison of Corneal Epitheliotrophic Factors of Undiluted Autologous Platelet-Rich Plasma and Autologous Serum Eye Drops for Dry Eye Disease. Ophthalmology and Therapy, 14, 363-377. https://doi.org/10.1007/s40123-024-01082-y
[8]
Lekhanont, K., Jongkhajornpong, P., Choubtum, L. and Chuckpaiwong, V. (2013) Topical 100% Serum Eye Drops for Treating Corneal Epithelial Defect after Ocular Surgery. BioMed Research International, 2013, Article ID: 521315. https://doi.org/10.1155/2013/521315
[9]
Quan, N.G., Leslie, L. and Li, T. (2023) Autologous Serum Eye Drops for Dry Eye: Systematic Review. Optometry and Vision Science, 100, 564-571. https://doi.org/10.1097/opx.0000000000002042
[10]
Franchini, M., Cruciani, M., Mengoli, C., et al. (2019) Serum Eye Drops for the Treatment of Ocular Surface Diseases: A Systematic Review and Meta-Analysis. Blood transfusion, 17, 200-209.
